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Introduction
Biologic agents for rheumatic diseases are powerful drugs
which may cause adverse events (AEs). It is important to
characterize AEs in long-term real-life setting in patients
with JIA.
Objectives
This study aimed to investigate the incidence of AEs during
biologic therapy in patients with JIA.
Methods
Data were collected from medical charts of 348 conse-
cutive patients with JIA from three tertiary centres in
Finland. Biologic therapy for these patients was started
1999-2009. AEs were categorized according to modified
Common Terminology Criteria for Adverse Events 4.0
(CTCAE) -criteriae.
Results
The follow-up time of the patients was altogether 1516
patient-years (py): 710 for etanercept, 591 for infliximab,
188 for adalimumab, and 27 for other biologic drugs. 216
(62%) patients were female. Median age at onset of JIA
was 4.7 years (0.7 to 15.9). Anti-TNF therapy was started
at a median age of 10.8 years (2.2 to 19.2). All patients had
either received DMARDs prior to anti-TNF or continued
receiving them concomitantly. Median follow-up time per
patient in this study was 50.5 months (1.0 to 154.7).
318 patients (91%) had at least one AE. Most common
AEs were infections; such as upper respiratory tract
infections, otitis media, sinusitis, and gastroenteritis
[44.4, 6.6, 5.7, and 4.8 per 100 py].
121 (34.7%) patients had a serious AE (SAE). Forty-four
patients had a serious infectious AE (3.8 AEs/100 py), of
which septicaemia (0.9/100 py) and pneumonia (0.7/100
py) were the most common.
The frequency of alanine aminotransferase elevation >5
times upper limit of normal was 1.7 per 100 py, and of
neutropenia 2.2 per 100 py.
AEs of special interest included new-onset colitis ulcer-
osa, Crohn’s disease, psoriasis, alopecia, or vasculitis in 4,
2, 9, 6, or 2 patients, respectively.
No malignancies were observed. Three patients had each
a cyst in spleen, brain or breast, and two had abnormal
pap smear findings. Two patients with severe systemic
onset JIA died after initiation of biologic treatment. Biolo-
gic drugs didn’t seem to differ from each other in terms of
the number of associated AEs. Since the patients may have
switched between several biologic agents, comparisons
between drug treatment groups were not possible.
Conclusion
Anti-TNF therapy is relatively safe in hands of pediatric
rheumatologists. However, one third of patients had a
serious AE, and for 100 patient-years, 3.8 serious infec-
tions were observed. Thus, careful monitoring is needed
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